DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.
Standard
DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. / Plöckinger, U; Hoffmann, U; Geese, M; Lupp, A; Buchfelder, M; Flitsch, Joerg; Vajkoczy, P; Jakob, W; Saeger, W; Schulz, S; Dohrmann, C.
In: EUR J ENDOCRINOL, Vol. 166, No. 2, 2, 2012, p. 223-234.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.
AU - Plöckinger, U
AU - Hoffmann, U
AU - Geese, M
AU - Lupp, A
AU - Buchfelder, M
AU - Flitsch, Joerg
AU - Vajkoczy, P
AU - Jakob, W
AU - Saeger, W
AU - Schulz, S
AU - Dohrmann, C
PY - 2012
Y1 - 2012
N2 - Somatostatin analogues (SSA) reduce autonomous GH secretion by activating somatostatin receptors (sst) 2 and 5 in 50-60% of acromegalic patients. However, by inhibiting insulin secretion these SSA reduce glucose tolerance. DG3173 is a novel SSA with additional binding to sst4 and low insulin-suppressing activity. We investigated the effect of DG3173, including its relation to specific tumour characteristics, on GH secretion in human somatotroph adenoma cell cultures (hSA) in comparison with Octreotide.
AB - Somatostatin analogues (SSA) reduce autonomous GH secretion by activating somatostatin receptors (sst) 2 and 5 in 50-60% of acromegalic patients. However, by inhibiting insulin secretion these SSA reduce glucose tolerance. DG3173 is a novel SSA with additional binding to sst4 and low insulin-suppressing activity. We investigated the effect of DG3173, including its relation to specific tumour characteristics, on GH secretion in human somatotroph adenoma cell cultures (hSA) in comparison with Octreotide.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Treatment Outcome
KW - Substrate Specificity
KW - Tumor Cells, Cultured
KW - Drug Evaluation, Preclinical
KW - Antineoplastic Agents, Hormonal/pharmacology/therapeutic use
KW - Down-Regulation/drug effects
KW - Adenoma/drug therapy/pathology/secretion/surgery
KW - Drug Resistance, Neoplasm/drug effects
KW - Growth Hormone-Secreting Pituitary Adenoma/drug therapy/pathology/secretion/surgery
KW - Human Growth Hormone/secretion
KW - Octreotide/therapeutic use
KW - Oligopeptides/pharmacology/therapeutic use
KW - Receptors, Somatostatin/agonists
KW - Somatostatin/analogs & derivatives/pharmacology
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Treatment Outcome
KW - Substrate Specificity
KW - Tumor Cells, Cultured
KW - Drug Evaluation, Preclinical
KW - Antineoplastic Agents, Hormonal/pharmacology/therapeutic use
KW - Down-Regulation/drug effects
KW - Adenoma/drug therapy/pathology/secretion/surgery
KW - Drug Resistance, Neoplasm/drug effects
KW - Growth Hormone-Secreting Pituitary Adenoma/drug therapy/pathology/secretion/surgery
KW - Human Growth Hormone/secretion
KW - Octreotide/therapeutic use
KW - Oligopeptides/pharmacology/therapeutic use
KW - Receptors, Somatostatin/agonists
KW - Somatostatin/analogs & derivatives/pharmacology
M3 - SCORING: Journal article
VL - 166
SP - 223
EP - 234
JO - EUR J ENDOCRINOL
JF - EUR J ENDOCRINOL
SN - 0804-4643
IS - 2
M1 - 2
ER -
